77 reports of this reaction
1.5% of all RUFINAMIDE reports
#16 most reported adverse reaction
CONVULSION is the #16 most commonly reported adverse reaction for RUFINAMIDE, manufactured by Eisai Inc.. There are 77 FDA adverse event reports linking RUFINAMIDE to CONVULSION. This represents approximately 1.5% of all 5,100 adverse event reports for this drug.
Patients taking RUFINAMIDE who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is a less commonly reported adverse event for RUFINAMIDE, but still significant enough to appear in the safety profile.
In addition to convulsion, the following adverse reactions have been reported for RUFINAMIDE:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 77 FDA reports for RUFINAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 1.5% of all adverse event reports for RUFINAMIDE, making it a notable side effect.
If you experience convulsion while taking RUFINAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.